AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KJUL 23 min read$NSPR

InspireMD, Inc. (NSPR): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001433607 0001433607 2026-06-26 2026-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor

Original reporting
SEC EDGAR 8-K
Published Jul 2, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$NSPR
Neutral
medium confidence
Mentioned
$NSPR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NSPRNeutralLow
01

Why it matters

The disclosure is primarily procedural (board vacancy and search for candidates) and does not cite disagreements with management or company operations.

02

Market read

Governance/board composition change is disclosed, but without stated operational disagreement, limiting immediate trading significance.

03

What to watch

Traders should watch for subsequent disclosures on committee assignments, any interim leadership changes, or whether the resignation triggers investor concerns about board oversight despite the “personal considerations” language.

Relevance 6/10Novelty 3/10Timing: after-hours/filing today (8-K filed July 2, 2026; resignation effective July 1)

Background

The filing is an SEC Form 8-K (Item 5.02) reporting a director resignation and the intent to fill the resulting vacancy.

Company-level read

Ticker impact

$NSPRNeutralMedium confidence
Context

InspireMD disclosed Raymond W. Cohen’s resignation from the board effective July 1, 2026, with the vacancy to be filled.

Expected impact

Likely limited near-term impact unless follow-on 8-Ks name a replacement or indicate strategic disagreement.

Evidence & confidence

The 8-K states the resignation is for personal considerations and not due to disagreement; it also notes the nominating committee will identify candidates, with no further specifics.

Market effects

Sector

Minimal; this is company-specific governance news with no stated sector-wide regulatory or competitive change.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If the replacement director is later tied to a specific strategy (e.g., commercialization, financing, or litigation oversight), the market may re-rate governance risk—this filing is only the first step.

Key entities

  • company
    InspireMD, Inc.

    Nasdaq-listed company filing the 8-K; subject of the director resignation disclosure.

  • person
    Raymond W. Cohen

    Class III board member who resigned effective July 1, 2026; resignation attributed to personal considerations.

  • board_committee
    Nominating and Corporate Governance Committee

    Committee that intends to identify and evaluate suitable candidates to fill the vacancy.

  • executive
    Marvin Slosman

    CEO signing the 8-K on July 2, 2026.

Read at source← All news

Related articles

AUG 20
$NSPRMed

InspireMD Q2 2026 Earnings: Revenue Misses $1.77 Million Estimate

InspireMD (NSPR) reported Q2 2026 revenue of $1.77M, missing estimates of $2.54M, and a net loss of $0.17 per share, beating expectations. Shares fell 7.06% due to revenue shortfall and U.S. recall impacts. The company expects FDA decisions on key products later in 2026. International revenue rose 21% YoY, while U.S. revenue was negative due to recall-related credits.

sci-tech-today.com2 min
AUG 17
Med

InspireMD, Inc. Q2 2026 Earnings Call Summary

InspireMD reported Q2 2026 results, citing flat revenue from a voluntary recall of its CGuard Prime 135 delivery system. Management said $734,000 in customer credits offset underlying U.S. growth, with a $612,000 inventory impairment and negative reported gross margin of 43.7%. It cut staff 20% and expects about $9M annual savings. FDA decisions for CGuard Prime 80 (TCAR) and CGuard CAS are targeted for Q4 2026, with Prime 135 reentry in H1 2027.

yahoo.com6 min
AUG 17
$NSPRMed

InspireMD Reports Second Quarter 2026 Financial Results

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InspireMD Reports Second Quarter 2026 Financial Results - Company to host investor conference call today, August 17 th , at 8:30am EDT - Miami, FL — August 17, 2026 – InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard ® Prime carot

SEC EDGAR 8-K6 min
JUN 11
$NSPRMedAI 8/10

InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures

InspireMD (Nasdaq: NSPR) reported 30-day results from its CGUARDIANS II trial of the CGuard Prime 80 cm implant for TCAR. In 50 high-risk patients, acute device success was 100% (50/50) with no deaths, strokes, MI, or stent thrombosis at 30 days. The company said an FDA PMA supplement is under review, with potential approval in H2 2026.

manilatimes.net5 min